# Nuvation Bio Inc. (NUVB) FY2026 Q2 Balance Sheet

- Company: Nuvation Bio Inc. (NUVB)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-06, accession number 0001193125-26-336646
- Page: https://plicit.ai/financials/nuvb/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/nuvb-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 744,503,000 US dollars
- **Current assets**: 726,432,000 US dollars
- **Non-current assets**: 18,071,000 US dollars
- **Liabilities**: 490,639,000 US dollars
- **Current liabilities**: 86,755,000 US dollars
- **Non-current liabilities**: 403,884,000 US dollars
- **Equity**: 253,864,000 US dollars
- **Marketable securities**: 402,352,000 US dollars
- **Cash and cash equivalents**: 258,604,000 US dollars
- **Accounts receivable, net of allowance for credit loss of $nil and $nil**: 27,826,000 US dollars
- **Inventory**: 19,901,000 US dollars
- **Prepaid expenses and other current assets**: 13,861,000 US dollars
- **Interest receivable on marketable securities**: 3,888,000 US dollars
- **Intangible assets, net of accumulated amortization of $2,777 and $1,856, respectively**: 10,292,000 US dollars
- **Other non-current assets**: 3,824,000 US dollars
- **Operating lease right-of-use assets**: 3,240,000 US dollars
- **Property and equipment, net of accumulated depreciation of $1,331 and $1,184, respectively**: 715,000 US dollars
- **Accrued expenses**: 45,204,000 US dollars
- **Liability related to revenue interest financing agreement, current portion**: 12,999,000 US dollars
- **Accounts payable**: 12,089,000 US dollars
- **Contract liabilities, current portion**: 8,855,000 US dollars
- **Short-term borrowings**: 5,893,000 US dollars
- **Current operating lease liabilities**: 1,715,000 US dollars
- **Warrant liability**: 0 US dollars
- **Convertible debt, net of deferred financing costs of $7,376**: 242,624,000 US dollars
- **Non-current liability related to revenue interest financing agreement, net of deferred financing costs of $3,818 and $4,241, respectively**: 151,122,000 US dollars
- **Contract liabilities, net of current portion**: 8,228,000 US dollars
- **Non-current operating lease liabilities**: 1,910,000 US dollars
- **Long-term borrowings, net of deferred financing costs of $3,042**: 0 US dollars
- **Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000, Class B 60,000,000 shares authorized as of June 30, 2026 and December 31, 2025 respectively 349,822,479 (Class A 348,822,479, Class B 1,000,000) and 346,503,675 (Class A 345,503,675, Class B 1,00,000) shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.**: 1,429,288,000 US dollars
- **Accumulated deficit**: negative 1,172,813,000 US dollars
- **Accumulated other comprehensive loss**: negative 2,611,000 US dollars
- **Gross equity (calculated)**: 1,429,288,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.